Evidence map›Paper›PMID 30875280›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Klaus-Peter Dieckmann, Arlo Radtke, Lajos Geczi, Cord Matthies, Petra Anheuser, Ulrike Eckardt, Jörg Sommer, Friedemann Zengerling, Emanuela Trenti, Renate Pichler and 29 more

Open access · hybridAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 4 pooled it
40.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 4 syntheses or guidelines pooled it, 334 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Is radiotherapy still an option for residual retroperitoneal masses in stage IIC seminoma?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 5 countries.

Klaus-Peter DieckmannAsklepios Klinik Altona, Hamburg, Germany.
Arlo Radtke3 University of Bremen, Bremen, Germany.
Lajos Geczi4 National Institute of Oncology, Budapest, Hungary.
Cord Matthies5 Bundeswehrkrankenhaus Hamburg, Hamburg, Germany.
Petra Anheuser2 Albertinen-Krankenhaus Hamburg, Hamburg, Germany.
Ulrike Eckardt6 St Elisabeth Krankenhaus, Leipzig, Germany.
Jörg Sommer7 St Franziskus Hospital, Lohne, Germany.
Friedemann Zengerling8 University of Ulm, Ulm, Germany.
Emanuela Trenti9 Krankenhaus Bozen, Bolzano, Italy.
Renate Pichler10 Medical University Innsbruck, Innsbruck, Austria.
Hanjo Belz11 Zeisigwaldkliniken, Chemnitz, Germany.
Stefan Zastrow12 Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
Alexander Winter13 Carl von Ossietzky University, Oldenburg, Germany.
Sebastian Melchior14 Klinikum Bremen-Mitte, Bremen, Germany.
Johannes Hammel14 Klinikum Bremen-Mitte, Bremen, Germany.
Jennifer Kranz15 St Antonius Hospital, Eschweiler, Germany.
Marius Bolten16 Ameos Klinikum, Geestland, Germany.
Susanne Krege17 Klinikum Essen-Mitte Huyssenstiftung, Essen, Germany.
Björn Haben18 St Marienkrankenhaus, Ahaus, Germany.
Wolfgang Loidl19 Ordensklinikum Barmherzige Schwestern, Linz, Austria.
Christian Guido Ruf20 Bundeswehrzentralkrankenhaus, Koblenz, Germany.
Julia Heinzelbecker21 Universitätsklinikum Saarland, Homburg, Germany.
Axel Heidenreich22 Universitätsklinikum Cologne, Cologne, Germany.
Jann Frederik Cremers23 Universitätsklinikum Münster, Münster, Germany.
Christoph Oing24 Universitätsklinikum Eppendorf, Hamburg, Germany.
Thomas Hermanns25 Universitätsspital Zürich, Zurich, Switzerland.
Christian Daniel Fankhauser25 Universitätsspital Zürich, Zurich, Switzerland.
Silke Gillessen26 Kantonsspital, St Gallen, Switzerland.
Hermann Reichegger26 Kantonsspital, St Gallen, Switzerland.
Richard Cathomas27 Kantonsspital Graubünden, Chur, Switzerland.
Martin Pichler28 Medical University Graz, Graz, Austria.
Marcus Hentrich29 Rotkreuzklinikum, Munich, Germany.
Klaus Eredics30 Kaiser Franz Josef Spital, Wien, Austria.
Anja Lorch31 Urologische Universitätsklinik der Heinrich Heine Universität, Düsseldorf, Germany.
Christian WülfingAsklepios Klinik Altona, Hamburg, Germany.
Sven Peine24 Universitätsklinikum Eppendorf, Hamburg, Germany.
Werner Wosniok3 University of Bremen, Bremen, Germany.
Carsten Bokemeyer24 Universitätsklinikum Eppendorf, Hamburg, Germany.
Gazanfer Belge3 University of Bremen, Bremen, Germany.
Universität Hamburg · DEUniversity of Bremen · DEAlbertinen Diakoniewerk · DEKantonsspital St. Gallen · CHKlinikum Bremen-Mitte · DEUniversity Hospital of Zurich · CHAGO Austria · ATAsklepios Klinik Altona · DEBundeswehrkrankenhaus · DEBundeswehrzentralkrankenhaus Koblenz · DECarl von Ossietzky Universität Oldenburg · DEDüsseldorf University Hospital · DEInnsbruck Medical University · ATKaiser-Franz-Josef-Spital · ATKantonsspital Graubünden · CHKliniken Essen-Mitte · DEMarienkrankenhaus Hamburg · DEMedical University of Graz · ATNational Institute of Oncology · HUOspedale di Bolzano · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrevious studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers of testicular germ cell tumors (GCTs) and are applicable toward both seminoma and nonseminoma. We sought to confirm the usefulness of this test as a novel biomarker for GCT. PATIENTS AND

methodsIn a prospective, multicentric study, serum samples of 616 patients with testicular GCTs and 258 male controls were examined for serum levels of miRNA-371a-3p (miR levels) by quantitative polymerase chain reaction. The GCT population encompassed 359 patients with seminoma and 257 with nonseminoma; 371 had clinical stage I disease, 201 had systemic disease, and 46 had relapses. Paired measurements before and after orchiectomy were performed in 424 patients; 118 with systemic disease had serial measurements during treatment. miR levels were compared with those of β-human chorionic gonadotropin, α-fetoprotein, and lactate dehydrogenase.

resultsFor the primary diagnosis of GCT, the M371 test showed a sensitivity of 90.1%, a specificity of 94.0%, an area under the curve of 0.966 upon receiver operating characteristic analysis, and a positive predictive value of 97.2%. α-Fetoprotein, β-human chorionic gonadotropin, and lactate dehydrogenase had sensitivities of less than 50% in seminoma and slightly higher sensitivities in nonseminomas. miR levels were significantly associated with clinical stage, primary tumor size, and response to treatment. Relapses had elevated miR levels that subsequently dropped to normal upon remission. Teratoma did not express miR-371a-3p.

conclusionThe M371 test outperforms the classic markers of GCT with both a sensitivity and a specificity greater than 90%. All histologic subgroups, except teratoma, express this marker. The test could be considered for clinical implementation after further validation.

Indexed as

AdolescentAdultAgedalpha-FetoproteinsBiomarkers, TumorCase-Control StudiesChorionic Gonadotropin, beta Subunit, HumanCirculating MicroRNAEuropeHumansL-Lactate DehydrogenaseMaleMicroRNAsMiddle AgedNeoplasms, Germ Cell and EmbryonalOrchiectomyAFP protein, humanalpha-FetoproteinsBiomarkers, TumorChorionic Gonadotropin, beta Subunit, HumanCirculating MicroRNAL-Lactate DehydrogenaseMicroRNAsMIRN371 microRNA, human

Identifiers

PMID30875280
PMCPMC6544462
OpenAlexW2922255797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.